


Ask a doctor about a prescription for EZETIMIBE/ATORVASTATIN CINFA 10 mg/80 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Ezetimibe/Atorvastatin cinfa 10 mg/10 mg film-coated tabletsEFG
Ezetimibe/Atorvastatin cinfa 10 mg/20 mg film-coated tabletsEFG
Ezetimibe/Atorvastatin cinfa 10 mg/40 mg film-coated tabletsEFG
Ezetimibe/Atorvastatin cinfa 10 mg/80 mg film-coated tabletsEFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Ezetimibe/atorvastatin is a medicine that lowers high cholesterol levels. Ezetimibe/atorvastatin contains ezetimibe and atorvastatin.
Ezetimibe/atorvastatin is used in adults to lower the levels of total cholesterol, "bad" cholesterol (LDL cholesterol) and a type of fat called triglycerides in the blood. It also raises the levels of "good" cholesterol (HDL cholesterol).
Ezetimibe/atorvastatin works by reducing cholesterol in two ways. It reduces the amount of cholesterol absorbed in the gut and the amount of cholesterol produced by the body.
Cholesterol is one of the fats found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol.
LDL cholesterol is often called "bad" cholesterol because it can build up in the walls of your arteries, forming plaques. Over time, this can lead to a narrowing of the arteries, which can reduce or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can cause a heart attack or stroke.
HDL cholesterol is often called "good" cholesterol because it helps prevent "bad" cholesterol from building up in the arteries and protects against heart disease.
Triglycerides are another type of fat found in the blood. High levels of triglycerides can increase the risk of heart disease.
Ezetimibe/atorvastatin is used in patients who cannot control their cholesterol levels by diet alone. While taking this medicine, you should also follow a cholesterol-lowering diet.
Ezetimibe/atorvastatin is used, along with a cholesterol-lowering diet, if you have:
Ezetimibe/atorvastatin does not help you lose weight.
Do not take Ezetimibe/Atorvastatin cinfa
Warnings and precautions
Consult your doctor or pharmacist before taking ezetimibe/atorvastatin
Contact your doctor as soon as possible if you experience unexplained muscle pain, tenderness or weakness while taking ezetimibe/atorvastatin.This is because, in rare cases, muscle problems can be serious, including muscle breakdown causing kidney damage. Atorvastatin is known to cause muscle problems and muscle problems have also been reported with ezetimibe.
Also, inform your doctor or pharmacist if you experience persistent muscle weakness. Further tests and additional medicines may be needed to diagnose and treat this condition.
Consult your doctor or pharmacist before taking ezetimibe/atorvastatin
If you are in any of the above situations (or are unsure), consult your doctor before taking ezetimibe/atorvastatin, as your doctor will need to perform a blood test before starting your treatment with ezetimibe/atorvastatin and possibly during treatment, to predict the risk you have of experiencing muscle side effects. It is known that the risk of experiencing muscle side effects, e.g. rhabdomyolysis, increases when certain medicines are taken at the same time (see section 2 "Taking Ezetimibe/Atorvastatin cinfa with other medicines").
While you are taking this medicine, your doctor will check if you have diabetes or are at risk of developing diabetes. This risk of diabetes increases if you have high levels of sugars and fats in the blood, are overweight and have high blood pressure.
Tell your doctor about all your medical conditions, including allergies.
The combined use of ezetimibe/atorvastatin and fibrates (certain medicines used to lower cholesterol) should be avoided, as the combined use of ezetimibe/atorvastatin and fibrates has not been studied.
Children
Ezetimibe/atorvastatin is not recommended for children and adolescents.
Other medicines and Ezetimibe/Atorvastatin cinfa
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those obtained without a prescription.
There are some medicines that may affect the way ezetimibe/atorvastatin works, or their effect may be altered by ezetimibe/atorvastatin (see section 3). This type of interaction could decrease the effectiveness of one or both medicines. On the other hand, it could also increase the risk or severity of side effects, including a serious disorder in which muscle tissue is broken down, known as "rhabdomyolysis", which is described in section 4:
** If you have to take fusidic acid by mouth to treat a bacterial infection, you will have to stop using this medicine temporarily. Your doctor will tell you when you can restart treatment with ezetimibe/atorvastatin. The use of this medicine with fusidic acid can rarely cause muscle weakness, tenderness or pain (rhabdomyolysis). For more information on rhabdomyolysis, see section 4
Taking Ezetimibe/Atorvastatin cinfa with food and drink
See section 3 for instructions on how to take ezetimibe/atorvastatin. Please note the following:
Grapefruit juice
Do not drink more than one or two small glasses of grapefruit juice per day, as large quantities of grapefruit juice can affect the action of ezetimibe/atorvastatin.
Alcohol
Avoid excessive alcohol consumption while taking this medicine. For more details, see section 2 "Warnings and precautions".
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take ezetimibe/atorvastatin if you can become pregnant, unless you use reliable contraceptive methods. If you become pregnant while taking ezetimibe/atorvastatin, stop taking it immediately and inform your doctor.
Do not take ezetimibe/atorvastatin if you are breast-feeding.
The safety of ezetimibe/atorvastatin during pregnancy and breast-feeding has not yet been established. Ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Ezetimibe/atorvastatin is unlikely to affect your ability to drive or use machines. However, it should be taken into account that some people experience dizziness after taking ezetimibe/atorvastatin.
Ezetimibe/Atorvastatin cinfa contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Ezetimibe/Atorvastatin cinfa 10 mg/10 mg, 10 mg/20 mg and 10 mg/40 mg contain lactose
If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Follow exactly the instructions of administration of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
Your doctor will determine the appropriate dose of ezetimibe/atorvastatin for you, depending on your current treatment and your personal risk situation.
? Before starting to take ezetimibe/atorvastatin, you should already be on a cholesterol-lowering diet.
? You should continue with this cholesterol-lowering diet while taking ezetimibe/atorvastatin.
How much to take
The recommended dose is one ezetimibe/atorvastatin tablet once a day by mouth.
Method of administration
Take ezetimibe/atorvastatin at any time of the day. You can take it with or without food.
If your doctor has prescribed ezetimibe/atorvastatin with colestyramine or any other bile acid sequestrant (medicines that lower cholesterol levels), you should take ezetimibe/atorvastatin at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If you take more Ezetimibe/Atorvastatin cinfa than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Ezetimibe/Atorvastatin cinfa
Do not take a double dose to make up for forgotten doses; the next day, take your normal dose of ezetimibe/atorvastatin at the usual time.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
If you experience any of the following serious adverse effects or symptoms, stop taking your tablets and inform your doctor immediately, or go to the emergency department of the nearest hospital.
Consult your doctor as soon as possible if you experience problems associated with the unexpected or unusual appearance of bleeding or bruising, as this fact may indicate a liver condition.
The following frequent adverse effects have been observed (may affect up to 1 in 10 patients):
The following infrequent adverse effects have been observed (may affect up to 1 in 100 patients):
The following adverse effects have been reported with an unknown frequency (the frequency cannot be estimated from the available data):
Consult your doctor if you experience weakness in the arms or legs that worsens after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or difficulty breathing.
Additionally, the following adverse effects have been reported in people taking ezetimibe/atorvastatin tablets, or ezetimibe or atorvastatin tablets alone:
Possible adverse effects observed with some statins
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and blister after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Ezetimibe/Atorvastatin cinfa
The active ingredients are ezetimibe and atorvastatin. Each film-coated tablet contains 10 mg of ezetimibe and 10 mg, 20 mg, 40 mg, or 80 mg of atorvastatin (as atorvastatin calcium trihydrate).
The other ingredients (excipients) are:
Tablet core:
Mannitol, sodium croscarmellose, povidone, sodium lauryl sulfate, magnesium stearate, microcrystalline cellulose, calcium carbonate, hydroxypropylcellulose, polysorbate 80, and yellow iron oxide (E-172).
Tablet coating:
Ezetimibe/Atorvastatin cinfa 10 mg/10 mg, 10 mg/20 mg, and 10 mg/40 mg
Opadry white (hypromellose, macrogol, titanium dioxide (E-171), and lactose monohydrate)
Ezetimibe/Atorvastatin cinfa 10 mg/80 mg
DrCoat FCU (hypromellose, titanium dioxide (E-171), talc, macrogol, yellow iron oxide (E-172))
Appearance of the Product and Package Contents
Ezetimibe/Atorvastatin cinfa 10 mg/10 mg: white, round, biconvex, film-coated tablets, approximately 8.1 mm in diameter.
Ezetimibe/Atorvastatin cinfa 10 mg/20 mg: white, oval, biconvex, film-coated tablets, approximately 11.6 x 7.1 mm in size.
Ezetimibe/Atorvastatin cinfa 10 mg/40 mg: white, capsule-shaped, biconvex, film-coated tablets, approximately 16.1 x 6.1 mm in size.
Ezetimibe/Atorvastatin cinfa 10 mg/80 mg: yellow, oblong, biconvex, film-coated tablets, approximately 19.1 x 7.6 mm in size.
Package sizes:
Blisters of OPA/Al/PVC//Al containing 30 film-coated tablets.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain
Manufacturer
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) – Spain
ELPEN Pharmaceutical Co. Inc.
Marathonos Avenue 95, Pikermi, Attiki,
190 09, Greece
ELPEN Pharmaceutical Co. Inc.
Zapani, Block 1048, Keratea,
190 01, Greece
Date of the Last Revision of this Leaflet: October 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
Ezetimibe/Atorvastatin cinfa 10 mg/10 mg film-coated tablets EFG
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/89581/P_89581.html
QR code to: https://cima.aemps.es/cima/dochtml/p/89581/P_89581.html
Ezetimibe/Atorvastatin cinfa 10 mg/20 mg film-coated tablets EFG
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/89582/P_89582.html
QR code to: https://cima.aemps.es/cima/dochtml/p/89582/P_89582.html
Ezetimibe/Atorvastatin cinfa 10 mg/40 mg film-coated tablets EFG
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/89583/P_89583.html
QR code to: https://cima.aemps.es/cima/dochtml/p/89583/P_89583.html
Ezetimibe/Atorvastatin cinfa 10 mg/80 mg film-coated tablets EFG
You can access detailed and updated information about this medicine by scanning the QR code included in the leaflet and packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/89584/P_89584.html
QR code to: https://cima.aemps.es/cima/dochtml/p/89584/P_89584.html
The average price of EZETIMIBE/ATORVASTATIN CINFA 10 mg/80 mg FILM-COATED TABLETS in December, 2025 is around 35.81 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for EZETIMIBE/ATORVASTATIN CINFA 10 mg/80 mg FILM-COATED TABLETS – subject to medical assessment and local rules.